Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients

被引：0
|
作者：
Liu, Yuting [1 ]
Zugazagoitia, Jon [1 ]
Henick, Brian [1 ]
Schalper, Kurt A. [1 ]
Rimm, David L. [1 ]
机构：
[1] Yale Univ, New Haven, CT USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2674
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2674
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy
    Li, Wei
    Wu, Fenglei
    Zhao, Shaolin
    Shi, Peiqin
    Wang, Shengjun
    Cui, Dawei
    CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 67 : 49 - 57
  • [32] Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML
    Zajac, Malgorzata
    Zaleska, Joanna
    Dolnik, Anna
    Siwiec, Anna
    Jankowska-Lecka, Olga
    Mlak, Radoslaw
    Ciesielka, Marzanna
    Gromek, Tomasz
    Sokolowska, Bozena
    Grzasko, Norbert
    Soroka-Wojtaszko, Maria
    Szudy-Szczyrek, Aneta
    Majdan, Maria
    Hus, Marek
    Bullinger, Lars
    Giannopoulos, Krzysztof
    BLOOD, 2016, 128 (22)
  • [33] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [34] ANALYSIS OF THE PD-1/PD-L1 AXIS POINTS TO ASSOCIATION OF UNFAVORABLE RECURRENT MUTATIONS WITH PD-L1 EXPRESSION IN AML
    Giannopoulos, K.
    Zajac, M.
    Zaleska, J.
    Dolnik, A.
    Siwiec, A.
    Jankowska-Lecka, O.
    Mlak, R.
    Ciesielka, M.
    Gromek, T.
    Sokolowska, B.
    Grzasko, N.
    Soroka-Wojtaszko, M.
    Szudy-Szczyrek, A.
    Majdan, M.
    Hus, M.
    Bullinger, L.
    HAEMATOLOGICA, 2017, 102 : 365 - 365
  • [35] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [36] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [37] The prognostic value of PD-L1/PD-1 expression and PD-L1 gene copy number on/in tumor and immune cells in triple negative breast cancer
    Seitz, S.
    Brockhoff, G.
    Weber, F.
    Klinkhammer-Schalke, M.
    Zeman, F.
    Ugocsai, P.
    Ortmann, O.
    Wege, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 4 - 4
  • [38] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [39] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [40] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
12345